PF614 (TAAP™ Oxycodone)

About Ensysce Biosciences

Ensysce Biosciences is pioneering a chemistry-first approach to prevent prescription drug abuse and overdose through its two proprietary technology platforms: TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance). The company's lead programs have received significant FDA designations, including Fast Track and Breakthrough Therapy, and it has secured approximately $12 million in non-dilutive grant funding from the National Institute on Drug Abuse. Ensysce is advancing its clinical pipeline with a focus on creating safer pain management therapies that could revolutionize the standard of care in a market with high unmet need.

Therapeutic Areas